ABC:NYE-AmerisourceBergen Corporation

EQUITY | Medical Distribution | New York Stock Exchange

Last Closing

USD 79.86

Change

0.00 (0.00)%

Market Cap

USD 17.27B

Volume

2.25M

Analyst Target

USD 92.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AmerisourceBergen Corp is a pharmaceutical services company. It provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers based in the United States and Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-20 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
MCK McKesson Corporation

-2.41 (-0.45%)

USD 69.10B
COR Cencora Inc.

-1.65 (-0.67%)

USD 38.52B
CAH Cardinal Health Inc

-0.64 (-0.57%)

USD 26.90B
OMI Owens & Minor Inc

-0.24 (-0.86%)

USD 1.89B
NVG Nuveen AMT Free Municipal Cred..

+0.09 (+0.75%)

USD 3.29M
SIGGF SIGGF

N/A

N/A

ETFs Containing ABC

CHEP 0.00 % 1.12 %

N/A

N/A
CWS AdvisorShares Focused Equ.. 0.00 % 0.68 %

+0.46 (+0%)

USD 0.14B
DEF 0.00 % 0.59 %

N/A

N/A
ESGF 0.00 % 0.40 %

N/A

N/A
FHC:CA First Trust Dow Jones Int.. 0.00 % 0.77 %

N/A

CAD 4.88M
FLAG 0.00 % 1.52 %

N/A

N/A
PWC 0.00 % 0.59 %

N/A

N/A
DVOL First Trust Dorsey Wright.. 0.00 % 0.60 %

+0.07 (+0%)

USD 0.05B
FHC-F:CA First Trust Dow Jones Int.. 0.00 % 0.00 %

N/A

CAD 5.68M
ECOZ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.34% 40% F 56% F
Dividend Return N/A N/A N/A N/A F
Total Return 7.34% 40% F 55% F
Trailing 12 Months  
Capital Gain -20.19% 100% F 23% F
Dividend Return 1.54% 50% F 29% F
Total Return -18.65% 100% F 22% F
Trailing 5 Years  
Capital Gain 13.23% 100% F 63% D
Dividend Return 9.36% 50% F 31% F
Total Return 22.59% 100% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 6.84% 100% F 71% C-
Dividend Return 8.40% 100% F 67% D+
Total Return 1.56% 50% F 32% F
Risk Return Profile  
Volatility (Standard Deviation) 25.96% 40% F 23% F
Risk Adjusted Return 32.37% 100% F 44% F
Market Capitalization 17.27B 80% B- 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Distribution) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.40 60% 55%
Price/Book Ratio 5.50 20% 12%
Price / Cash Flow Ratio 3.11 20% 39%
Price/Free Cash Flow Ratio 15.91 20% 37%
Management Effectiveness  
Return on Equity 54.86% 100% 95%
Return on Invested Capital 21.45% 100% 84%
Return on Assets 4.40% 80% 64%
Debt to Equity Ratio 145.00% 60% 24%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.